Literature DB >> 18784477

Update on the propofol infusion syndrome in ICU management of patients with head injury.

Luuk C Otterspoor1, Cornelis J Kalkman, Olaf L Cremer.   

Abstract

PURPOSE OF REVIEW: The propofol infusion syndrome is a rare condition characterized by the occurrence of lactic acidosis, rhabdomyolysis and cardiovascular collapse following high-dose propofol infusion over prolonged periods of time. Patients with traumatic brain injury are particularly at risk of developing this complication because large doses of propofol are commonly used to control intracranial pressure, whereas vasopressors are administered to augment cerebral perfusion pressure. In this review, we provide an update on the literature with particular emphasis on patients with traumatic brain injury. RECENT
FINDINGS: Several new case reports and reviews, as well as a number of experiments, have contributed significantly to our increased understanding of the cause of the syndrome. At the basis of the syndrome lies an imbalance between energy utilization and demand resulting in cell dysfunction, and ultimately necrosis of cardiac and peripheral muscle cells. Uncertainty remains whether a genetic susceptibility exists. Nonetheless, the growing number of case reports has made it possible to identify several risk factors.
SUMMARY: Propofol infusion syndrome is a rare but frequently lethal complication of propofol use. In patients with risk factors, such as traumatic brain injury, it is suggested that an infusion rate of 4 mg/kg per hour should not be exceeded. Early warning signs include unexplained lactic acidosis, lipemia and Brugada-like ECG changes. When these occur, propofol infusion should be discontinued immediately.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18784477     DOI: 10.1097/ACO.0b013e32830f44fb

Source DB:  PubMed          Journal:  Curr Opin Anaesthesiol        ISSN: 0952-7907            Impact factor:   2.706


  16 in total

1.  Lipid metabolism disturbances and AMPK activation in prolonged propofol-sedated rabbits under mechanical ventilation.

Authors:  Wei Jiang; Zheng-bo Yang; Quan-hong Zhou; Xiang Huan; Li Wang
Journal:  Acta Pharmacol Sin       Date:  2011-12-12       Impact factor: 6.150

2.  Posttreatment with propofol attenuates lipopolysaccharide-induced up-regulation of inflammatory molecules in primary microglia.

Authors:  Mian Peng; Ji-Shi Ye; Yan-Lin Wang; Chang Chen; Cheng-Yao Wang
Journal:  Inflamm Res       Date:  2014-02-01       Impact factor: 4.575

3.  Propofol infusion syndrome heralded by ECG changes.

Authors:  Elsbeth J Mijzen; Bram Jacobs; Adnan Aslan; Michael G G Rodgers
Journal:  Neurocrit Care       Date:  2012-10       Impact factor: 3.210

4.  Vasopressors and propofol infusion syndrome in severe head trauma.

Authors:  Heidi Smith; Grant Sinson; Panayiotis Varelas
Journal:  Neurocrit Care       Date:  2008-12-03       Impact factor: 3.210

5.  A death associated with possible propofol infusion syndrome.

Authors:  Nikhil Agrawal; Sudhakar Rao; Roshan Nair
Journal:  Indian J Surg       Date:  2012-09-22       Impact factor: 0.656

6.  Recovery following propofol-associated brugada electrocardiogram.

Authors:  Justin B Weiner; Elias V Haddad; Satish R Raj
Journal:  Pacing Clin Electrophysiol       Date:  2009-10-10       Impact factor: 1.976

7.  Propofol infusion syndrome or not? A case report.

Authors:  James H Diaz; Cory A Roberts; Josh J Oliver; Alan David Kaye
Journal:  Ochsner J       Date:  2014

8.  Sedation in traumatic brain injury.

Authors:  Oliver Flower; Simon Hellings
Journal:  Emerg Med Int       Date:  2012-09-20       Impact factor: 1.112

9.  Anesthetic drug development: Novel drugs and new approaches.

Authors:  Hovig V Chitilian; Roderic G Eckenhoff; Douglas E Raines
Journal:  Surg Neurol Int       Date:  2013-03-19

10.  The propofol infusion syndrome: more puzzling evidence on a complex and poorly characterized disorder.

Authors:  Olaf L Cremer
Journal:  Crit Care       Date:  2009-12-07       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.